People · Operator
Named in public records as an officer, director or promoter · active 2016–2019 · Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| ESSA Pharma Inc. | — | Pharmaceuticals | Series B | $56.0M | $1.2B | 2016 |
Gary Sollis at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Gary Sollis on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| David Wood | 1 | 8 |
| Franklin Berger | 1 | 7 |
| Scott Requadt | 1 | 5 |
| David Parkinson | 1 | 3 |
| John Alex Martin | 1 | 2 |
| Richard Glickman | 1 | 2 |
| Peter Virsik | 1 | 1 |
| Otello Alex Stampacchia | 1 | 1 |
| Ann Marella Thorell | 1 | 1 |
| Frank Perabo | 1 | 1 |
| Raymond Andersen | 1 | 1 |
| Paul Cossum | 1 | 1 |
| Marianne Sadar | 1 | 1 |
| Sandy Marella Zweifach | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.